Atypical Antipsychotic class drugs

11 results

  • abilify

    (ARIPIPRAZOLE)
    Otsuka America Pharmaceutical, Inc.
    ABILIFY (aripiprazole) is indicated for the treatment of schizophrenia, acute manic and mixed episodes associated with Bipolar I Disorder, adjunctive treatment of major depressive disorder, irritability associated with autistic disorder, and treatment of Tourette's disorder.

  • abilify asimtufii

    (Aripiprazole)
    Otsuka America Pharmaceutical, Inc
    ABILIFY ASIMTUFII is indicated for the treatment of schizophrenia in adults and for maintenance monotherapy of bipolar I disorder in adults.

  • abilify maintena

    (aripiprazole)
    Otsuka America Pharmaceutical, Inc.
    ABILIFY MAINTENA (aripiprazole) is indicated for the treatment of schizophrenia and as maintenance monotherapy for bipolar I disorder in adults.

  • abilify mycite

    (ARIPIPRAZOLE)
    Otsuka America Pharmaceutical, Inc.
    ABILIFY MYCITE is indicated for treating adults with schizophrenia, bipolar I disorder (including both acute and maintenance phases), and as adjunctive therapy for Major Depressive Disorder. It features an Ingestible Event Marker (IEM) sensor to track medication ingestion.

  • caplyta

    (lumateperone)
    Intra-Cellular Therapies, Inc
    CAPLYTA is indicated for treating schizophrenia in adults and for depressive episodes associated with bipolar I or II disorder in adults, both as monotherapy and as adjunctive therapy with lithium or valproate.

  • fanapt

    (iloperidone)
    Vanda Pharmaceuticals Inc.
    FANAPT® is indicated for the treatment of schizophrenia in adults and for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults.

  • geodon

    (ziprasidone hydrochloride)
    ROERIG
    GEODON is indicated for treating schizophrenia, acute manic or mixed episodes of bipolar I disorder (both as monotherapy and adjunct to lithium or valproate), and for acute agitation in schizophrenic adults needing rapid control. Caution is advised due to potential QT/QTc interval prolongation risks.

  • invega sustenna

    (paliperidone palmitate)
    Janssen Pharmaceuticals, Inc.
    INVEGA SUSTENNA (paliperidone palmitate) is indicated for the treatment of schizophrenia and schizoaffective disorder in adults, both as monotherapy and as an adjunct to mood stabilizers or antidepressants.

  • lybalvi

    (olanzapine and samidorphan L-malate)
    Alkermes, Inc.
    LYBALVI is indicated for the treatment of schizophrenia in adults and for Bipolar I disorder in adults, including acute treatment of manic or mixed episodes (as monotherapy or adjunct to lithium/valproate) and maintenance monotherapy.

  • nuplazid

    (pimavanserin tartrate)
    Acadia Pharmaceuticals Inc.
    NUPLAZID® is indicated for treating hallucinations and delusions associated with Parkinson's disease psychosis.